Cargando…
A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia
Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327549/ https://www.ncbi.nlm.nih.gov/pubmed/35584397 http://dx.doi.org/10.1182/bloodadvances.2022007854 |